

19 **ABSTRACT**

20 Ubiquitin signaling controls many aspects of eukaryotic biology, including targeted protein
21 degradation and immune defense. Remarkably, invading bacterial pathogens have adapted
22 secreted effector proteins that hijack host ubiquitination to gain control over host responses.
23 These ubiquitin-targeted effectors can exhibit, for example, E3 ligase or deubiquitinase activities,
24 often without any sequence or structural homology to eukaryotic ubiquitin regulators. Such
25 convergence in function poses a challenge to the discovery of additional bacterial virulence
26 factors that target ubiquitin. To overcome this, we have developed a workflow to harvest natively
27 secreted bacterial effectors and functionally screen them for ubiquitin regulatory activities. After
28 benchmarking this approach on diverse ligase and deubiquitinase activities from *Salmonella*
29 Typhimurium, Enteropathogenic *Escherichia coli*, and *Shigella flexneri*, we applied it to the
30 identification of a cryptic E3 ligase activity secreted by *Pseudomonas aeruginosa*. We identified
31 an unreported *P. aeruginosa* E3 ligase, which we have termed *Pseudomonas* Ub ligase 1 (PUL-
32 1), that resembles none of the other E3 ligases previously established in or outside of the
33 eukaryotic system. Importantly, in an animal model of *P. aeruginosa* infection, PUL-1 ligase
34 activity plays an important role in regulating virulence. Thus, our workflow for the functional
35 identification of ubiquitin-targeted effector proteins carries promise for expanding our
36 appreciation of how host ubiquitin regulation contributes to bacterial pathogenesis.

37

38 **KEYWORDS**

39 Ubiquitin, ubiquitin ligase, deubiquitinase, bacterial effector, *Pseudomonas aeruginosa*

40

41 INTRODUCTION

42 Signaling networks mediated by the post-translational modifier ubiquitin regulate a vast domain
43 of eukaryotic biology. Through a process termed ubiquitination, the 76-amino acid protein
44 ubiquitin (Ub) is conjugated via its C-terminus onto target proteins, typically at lysine (Lys, K)
45 residues, to trigger signaling outcomes such as trafficking or degradation. The diversity in Ub-
46 dependent signaling outcomes arises, in part, from the extension of polymeric Ub (polyUb)
47 chains that act as distinct signaling molecules. For example, polyUb chains linked via K48 form
48 the classical signal for proteasomal degradation, while those linked via K63 are non-degradative
49 and facilitate protein recruitment in pathways such as endocytosis, immune activation, or the
50 DNA damage response^{1,2}. Ub conjugation is heavily regulated by a cascade of E1 Ub-activating,
51 E2 Ub-conjugating, and E3 Ub ligase enzymes, while deconjugation is mediated by
52 deubiquitinases (DUBs). E3 ligases represent the largest set of Ub regulators, with over 600
53 examples in humans. With few exceptions^{3,4}, human E3 ligases fall into roughly three
54 structurally and mechanistically distinct families: Really Interesting New Gene (RING) ligases⁵,
55 Homologous to E6AP C-terminus (HECT) ligases⁶, and RING-between-RING (RBR) ligases⁷.
56 While RING ligases catalyze direct Ub conjugation from an E2~Ub intermediate onto a
57 substrate, HECT and RBR ligases form a final E3~Ub intermediate, in which the Ub C-terminus
58 is activated onto an active site cysteine (Cys, C) through a high-energy thioester linkage. These
59 three mechanisms of Ub conjugation are highly conserved across eukaryotic biology.

60

61 Remarkably, despite lacking a canonical Ub system of their own, pathogenic viruses and bacteria
62 have evolved virulence factors capable of regulating Ub signaling of their eukaryotic hosts^{8,9}.
63 Bacteria, in particular, have evolved a multitude of strategies to redirect, block, or eliminate host
64 Ub signaling through the action of secreted ‘effector’ proteins¹⁰. While some of these strategies
65 of Ub regulation mimic those used by eukaryotes, others appear to be entirely distinct and likely
66 arose through convergent evolution⁸. Bacterial E3 ligases, for example, fall into at least seven
67 distinct families, only one of which resembles eukaryotic RING ligases. Stemming from this
68 convergent nature, the identification of bacterial Ub regulators has been cumbersome and limited
69 to select pathogens. Previous efforts have relied upon labor-intensive approaches, such as
70 individual mapping of protein-protein interactions^{11,12}, or introduce a heavy bias toward known

71 enzymes and mechanisms, such as sequence/structural homology or the use of activity-based
72 probes (ABPs)¹³⁻¹⁵. On the other hand, a functional approach focused on bacterial DUBs specific
73 to linear (M1-linked) polyUb chains identified an effector protein from *Legionella pneumophila*
74 that is distinct from any DUB families previously observed in eukaryotes, viruses, or bacteria¹⁶.
75 An unbiased discovery approach, therefore, has the potential to identify unprecedented Ub
76 regulators that mediate bacterial virulence.

77
78 From the animal and plant pathogens that have been studied thus far, it has become increasingly
79 clear that subversion of host Ub signaling is a commonly adopted virulence strategy. The
80 gastrointestinal pathogen *Shigella flexneri*, for example, has devoted nearly one-third of its
81 effector repertoire toward regulating the Ub system¹⁷. Still, other medically relevant pathogens,
82 with elaborate mechanisms of host manipulation, lack any described methods to regulate host
83 ubiquitination. Among them, *Pseudomonas aeruginosa* represents a critical target for developing
84 an improved understanding of host-pathogen interactions. *P. aeruginosa* is an opportunistic,
85 Gram-negative pathogen that poses a severe health risk for immunocompromised individuals and
86 is among the leading causes of nosocomial infections. It is also of extreme concern for
87 antimicrobial resistance, as highly resistant strains of *P. aeruginosa* were associated with over
88 300,000 deaths worldwide in the year 2019 alone, representing a massive and increasing health
89 burden¹⁸. *P. aeruginosa* encodes a large repertoire of virulence factors, including a Type III
90 Secretion System (T3SS) known to secrete a combination of ExoU, ExoS, ExoT, and ExoY
91 effector proteins into the host cell¹⁹. While ExoT levels are regulated by host ubiquitination and
92 ExoU phospholipase activity requires Ub as a cofactor^{20,21}, no *P. aeruginosa* effectors have been
93 identified to directly regulate host Ub signaling. Furthermore, no Ub regulators are readily
94 apparent from sequence and structural homology analyses, raising question as to whether *P.*
95 *aeruginosa* has not adapted strategies to regulate ubiquitination, or if cryptic Ub regulators
96 remain to be discovered.

97
98 Herein, we developed a novel unbiased method to survey Ub regulatory activities of natively
99 secreted bacterial effectors. By stimulating secretion in culture, pools of bacterial effector
100 proteins could be harvested as input for highly sensitive, fluorescence-based assays of Ub

101 regulatory activities. In this manner, secreted ligase and DUB activities were observable from
102 *Salmonella* Typhimurium, enteropathogenic *Escherichia coli* (EPEC), and *S. flexneri*, consistent
103 with previous reports²²⁻²⁵. Applying this approach to *P. aeruginosa*, we identified a cryptic E3
104 ligase activity from the gene product PA2552, which we have renamed to *Pseudomonas* Ub
105 ligase 1 (PUL-1). *In vitro*, PUL-1 catalyzes a mixture of mono- and polyubiquitination
106 downstream of human E1 and E2 enzymes. Interestingly, PUL-1 represents an uncharacterized
107 family of Cys-based E3 ligases that are conserved among *P. aeruginosa* clinical isolates as well
108 as other bacterial pathogens. *In vivo*, the ligase activity of PUL-1 modulates *P. aeruginosa*
109 virulence in a *C. elegans* model of infection. Thus, the approach we describe offers a
110 straightforward and unbiased opportunity to identify cryptic Ub regulators secreted as virulence
111 factors by bacterial pathogens.

112

113 RESULTS

114 A functional screen for ubiquitin regulation

115 To overcome the challenge of identifying evolutionarily convergent bacterial effectors that
116 regulate ubiquitination, we sought to implement an unbiased functional approach. As sensitive
117 and robust measures for Ub conjugation and deconjugation are readily available, the primary
118 obstacle was isolation of candidate bacterial effector molecules. To eliminate contributions from
119 the eukaryotic Ub regulatory system that would come with bacterial infections, we instead
120 utilized established conditions that artificially stimulate effector secretion in bacterial culture. In
121 many cases, these stimulatory conditions mimic native cues sensed by the bacterial secretion
122 systems, such as lowered pH that triggers the *S. Typhimurium* SPI-II T3SS in the context of an
123 acidified vacuole²⁶. Following stimulation, secreted effectors could be harvested from the culture
124 supernatant, concentrated by native ammonium sulfate precipitation, and resolubilized for
125 biochemical activity assays (**Fig. 1A**). Meanwhile, a bacterial lysate could be prepared from the
126 culture pellet, for comparison to the secreted protein fraction (**Fig. 1A**). As an alternative to
127 stimulation, strains with mutations in secretion regulators, leading to constitutive secretion, can
128 be used in a similar workflow. *S. flexneri*, EPEC, and *S. Typhimurium* were selected for proof-
129 of-principle experiments, as *S. Typhimurium* encodes a reported DUB²², and all three encode
130 reported E3 ligases²³⁻²⁵. *S. flexneri* effector secretion can be triggered with Congo Red or with

131 the constitutively-secreting $\Delta ipaD$ mutant^{27,28}, EPEC secretion can be triggered by pH and salt
132 conditions commonly present in Dulbecco's modified Eagle's medium (DMEM)²⁹, while the
133 SPI-I and SPI-II secretion systems of *S. Typhimurium* can be triggered with changes in salt or
134 pH, respectively^{26,30,31} (**Fig. 1B**). Under these conditions, we could harvest natively secreted
135 effector repertoires that were distinct from the lysate fractions, and unique to each bacterial
136 secretion system (**Fig. 1B**).

137

138 Among the methods to detect Ub conjugation and deconjugation *in vitro*, those that utilize
139 fluorescence polarization (FP) offer both broad applicability as well as high sensitivity.
140 Deconjugation activity can be readily measured as a decrease in FP following cleavage of a Ub-
141 KG(Tamra) substrate, in which Ub is natively isopeptide-linked to the ϵ -amino group of a
142 fluorescent KG dipeptide³² (**Fig. 1C**). This substrate has been heavily used to characterize
143 eukaryotic as well as bacterial DUBs^{13,32,33}. The *S. Typhimurium* SPI-II secretion system
144 reportedly delivers the DUB SseL into host cells²². Consistently, we observe cleavage of the Ub-
145 KG(Tamra) substrate upon addition of the *S. Typhimurium* SPI-II secreted fraction (**Fig. 1D**).
146 This activity is abolished upon boiling the secreted fraction, and is restricted to only the lysate
147 fraction when prepared from a SPI-II secretion-deficient $\Delta ssaR$ mutant strain^{34,35} (**Fig. 1D**).
148 Thus, our approach can readily detect natively secreted DUB activity among bacterial effectors.

149

150 Using a recently developed method called UbiReal^{36,37}, Ub conjugation can also be monitored by
151 FP. In this case, a fluorescently labeled Ub is conjugated through the E1-E2-E3 cascade,
152 resulting in relative increases in molecular weight that coincide with increased FP (**Fig. 1E**). This
153 approach has been effective in characterizing both eukaryotic and bacterial E3 ligases³⁶⁻³⁸. *S.*
154 *Typhimurium* encodes four reported E3 ligases: the HECT-like effector SopA secreted by SPI-I
155 and three NEL (novel E3 ligase) effectors secreted by SPI-II^{23,25,39,40}. In a UbiReal assay that
156 combines the two most promiscuous E2 enzymes⁴¹, UBE2D3 and UBE2L3, ligase activity
157 consistent with SopA is observed in the SPI-I secreted fraction (**Fig. 1F**). Consistent with their
158 reported auto-inhibited state in the absence of substrate⁴², we observe no ligase activity from
159 NEL effectors in the SPI-II secreted fraction. The SPI-I secreted ligase activity can be reversed
160 upon addition of the nonspecific DUB, vOTU⁴³ (**Fig. 1F**). The activity is also ablated upon

161 boiling of the secreted fraction, and is restricted to the SPI-I lysate fraction when prepared from a
162 SPI-I secretion-deficient $\Delta prgI$ mutant strain^{44,45} (**Fig. 1F**). The E2348/69 strain of EPEC
163 reportedly encodes an E3 ligase from the NleG family²⁴, while *S. flexneri* reportedly encodes
164 multiple NEL-family ligases²⁵. Consistently, E3 ligase activity is observed in the EPEC and *S.*
165 *flexneri* secreted fractions in UbiReal assays utilizing the highly promiscuous E2 UBE2D3 (**Fig.**
166 **1G**). However, while *S. Typhimurium* SopA and the *S. flexneri* NEL effectors utilize a Cys-
167 dependent ligase mechanism, the EPEC NleG-type ligase utilizes a cysteine-independent
168 mechanism akin to eukaryotic RING and U-box ligases. Accordingly, in UbiReal assays that
169 incorporate the Cys-specific E2 UBE2L3, activity is only observed for *S. Typhimurium* SPI-I
170 and *S. flexneri* secreted fractions (**Fig. 1H**). The E2- and cysteine-dependent nature of the
171 secreted ligase activities can also be confirmed by conventional western blotting approaches
172 (**Fig. S1A-C**). Thus, not only can natively secreted E3 ligase activities be observed with this
173 approach, but the type of activity can be characterized as well.

174

175 **Detection of E3 ligase activity secreted by *P. aeruginosa***

176 With proof-of-principle for the functional approach established, we sought to screen for
177 unidentified Ub regulatory activities. The opportunistic pathogen *P. aeruginosa* exploits a gamut
178 of virulence mechanisms, including a T3SS, to infect a wide range of eukaryotic hosts. Despite
179 several connections between its T3SS effectors and the host Ub system^{20,21}, a mechanism of
180 direct Ub regulation has not been identified. Using the PAO1 and PA14 reference strains of *P.*
181 *aeruginosa*, we triggered effector secretion with an established calcium depletion approach⁴⁶,
182 and harvested the secreted and lysate fractions (**Fig. 2A**). These *P. aeruginosa* secreted fractions
183 were notably more complex than those obtained from, e.g., *S. flexneri*, but were still distinct
184 from the lysate fractions. Remarkably, introducing the PA14 secreted fraction into a UbiReal
185 assay immediately revealed the presence of E3 ligase activity that could be reversed by addition
186 of purified DUB (**Fig. 2B**). This ligase activity was also present in the PAO1 secreted fraction,
187 and appeared to utilize a Cys-dependent mechanism, as activity was observed with both
188 UBE2D3 and UBE2L3 (**Fig. 2C**). Further supporting a cysteine-based mechanism, the ligase
189 activity was ablated following pre-treatment with either the Cys-reactive N-ethylmaleimide
190 (NEM) or with Proteinase K (**Fig. 2D**). Consistent with other secreted virulence factors, the

191 presence of ligase activity in the secreted fraction required calcium depletion (**Fig. 2D**). While
192 the ligase activity was independent of the two-component system regulator GacA, its secretion
193 did require the transcription regulator ExsA, which controls the T3SS regulon⁴⁷ (**Fig. 2E, S2A**).
194 Thus far, the repertoire of established T3SS effectors in PA14 is limited to ExoT, ExoU, and
195 ExoY, yet the secreted fraction harvested from a $\Delta ExoTUY$ triple-mutant strain retained the
196 observed E3 ligase activity (**Fig. 2E**). Interestingly, to varying degrees, the ligase activity is also
197 widely observed among a panel of 14 other *P. aeruginosa* clinical isolates (**Fig. 2F, S2B-C**).
198 These data suggest the presence of an unidentified secreted E3 ligase among the repertoire of
199 ExsA-dependent *P. aeruginosa* virulence factors.

200

201 **Identification of a *P. aeruginosa* E3 ligase**

202 In an initial effort to further purify the secreted ligase activity, the PA14 secreted fraction was
203 resubjected to more refined, stepwise ammonium sulfate precipitations (**Fig. 3A**). This process
204 separated defined protein bands in the 20-50% ammonium sulfate range from the much more
205 complex components in the 50-80% ammonium sulfate range. Among these fractions, the 30-
206 40% ammonium sulfate fraction contained the highest amount of ligase activity (**Fig. 3B, S3A**).
207 Given the Cys-based mechanism of the secreted ligase (**Fig. 2C-D**), the 20-30% and 30-40%
208 secreted fractions were subjected to labeling with the E1-E2-E3 cascading activity-based probe,
209 Ub-DHA, which employs a dehydroalanine (DHA) warhead at its C-terminus to covalently
210 capture Ub-conjugating enzymes⁴⁸. As expected, a biotinylated Ub-DHA probe labeled the E1
211 (UBE1) and E2 (UBE2D3) in the reaction (**Fig. 3C**). Upon addition of *P. aeruginosa* secreted
212 fractions, additional Ub-DHA-reactive bands were identified that increased in intensity between
213 the 20-30% and 30-40% fractions (**Fig. 3C**). Following visualization with a fluorescently-labeled
214 Ub-DHA probe, these reactive bands were excised and analyzed by mass spectrometry.
215 Candidate proteins identified from the activity-based probe mass spectrometry (ABP-MS)
216 analysis were combined with candidates identified in a bioinformatics approach using the Ub-
217 SIEVE model¹⁵, and the resulting list was screened by preparing secreted fractions from the
218 associated PAO1 and PA14 transposon mutant strains for testing in UbiReal^{49,50}. Among this list
219 of candidates, as well as the established T3SS effectors, only the *PAOI_2552*^{Tn} strain (carrying
220 an inactivating transposon inserted into PA2552) exhibited a loss in secreted ligase activity (**Fig.**

221 **3D**). In a conventional western blot approach, the *PAOI_2552*^{Tn} secreted fraction lacked nearly
222 all ligase activity, compared to the wild-type PAO1 strain (**Fig. S3B**). We therefore renamed
223 PA2552 to *Pseudomonas* Ub ligase 1 (PUL-1). A full kinetic UbiReal profile of the *pul-1*^{Tn}
224 secreted fraction showed a considerable loss in ligase activity, which was restored to wild-type
225 levels when *pul-1* was reintroduced into the transposon mutant strain on a plasmid with its native
226 promoter region (**Fig. 3E**). Under these conditions, PUL-1 therefore appears to be the
227 predominant E3 ligase secreted by *P. aeruginosa*.

228

229 **Characterization of PUL-1 E3 ligase activity**

230 To further characterize its ligase activity, the *pul-1* gene was cloned from PAO1 and used for
231 recombinant protein expression in *E. coli* (**Fig. 4A**). An *in vitro* ubiquitination reaction with
232 purified PUL-1 showed robust polyUb chain formation, including unanchored diUb as well as
233 longer, high molecular weight chains (**Fig. 4B**). As was the case with the *P. aeruginosa* secreted
234 fraction, the ligase activity of purified PUL-1 could be reversed with the nonspecific DUB
235 USP21⁴³, and additionally could be inhibited by pre-treatment with NEM (**Fig. 4B**). As expected,
236 purified PUL-1 is also labeled with the Ub-DHA probe in a time-dependent manner, and
237 produces an ~55 kDa band that matches a reactive band observed in the *P. aeruginosa* secreted
238 fraction (**Fig. 4C**). Across a panel of E2 enzymes, PUL-1 is active with the UBE2D family
239 (particularly UBE2D1 and UBE2D2), UBE2L3, and UBE2W (**Fig. 4D, S4A**). The E3-
240 independent activities of UBE2K and UBE2S were also slightly higher in the presence of PUL-1.
241 The form of polyUb produced by PUL-1 was examined using a Ub chain restriction (UbiCRest)
242 analysis, which involves subjecting PUL-1 polyUb products to a panel of linkage-specific DUBs
243 and examining their cleavage patterns⁴³. Only treatment with the nonspecific DUBs vOTU and
244 USP21, or the combination of all linkage-specific DUBs, resulted in appreciable cleavage of
245 PUL-1 products (**Fig. 4E**). This behavior is consistent with products comprised of
246 monoubiquitination and nonspecific polyubiquitination. The same behavior is observed with
247 panels of K-only or K-to-R Ub mutants, which indicate no specificity in the type of polyUb
248 formed by PUL-1 (**Fig. S4B-C**). To test whether PUL-1 products are defined by a conventional,
249 Lys-Ub linkage, the conditions of the PUL-1 ubiquitination reaction were optimized to capture
250 the transient, PUL-1~Ub intermediate, in which Ub is loaded onto the PUL-1 active site Cys

251 (Fig. 4F). As expected, this activated PUL-1~Ub thioester intermediate is reactive toward the
252 reducing agent dithiothreitol (DTT) as well as the amino acid Cys. Among the panel of other
253 amino acids tested, however, PUL-1 was only capable of discharging Ub onto Lys, suggesting a
254 specificity toward conventional Ub linkages (Fig. 4F). Consistently, mass spectrometry analysis
255 of an *in vitro* PUL-1 ubiquitination reaction identified three sites of PUL-1 Lys auto-
256 ubiquitination as well as formation of K6, K11, K27, K33, K48, and K63 polyUb linkages (Fig.
257 S4D).

258

259 Structural analysis of the PUL-1 E3 ligase fold

260 Although no experimental structure of PUL-1 is currently available, the AlphaFold2 model
261 exhibits very high confidence, with predicted local distance difference test (pLDDT) scores of
262 >90 throughout most of the 375-residue sequence⁵¹ (Fig. 5A). The modeled structure shows high
263 similarity to an acyl-CoA dehydrogenase fold, and a Dali structural homology analysis highlights
264 high similarity to short chain acyl-CoA dehydrogenases from bacterial as well as eukaryotic
265 origin⁵². Crystal structures of homologous folds from *Burkholderia thailandensis* BTH_II1803
266 and the rat mitochondrial short-chain specific acyl-CoA dehydrogenase (SCAD) align to the
267 PUL-1 model with less than 1 Å RMSD⁵³ (Fig. 5B). Residues at the acyl-CoA-binding site, as
268 well as the cofactor FAD-binding site, are highly conserved among PUL-1 and rat SCAD (Fig.
269 S5A-B). Despite this similarity, PUL-1 demonstrated no dehydrogenase activity against an
270 octanoyl-CoA substrate, unlike the highly similar *Mycobacterium tuberculosis* FadE13 enzyme
271 (Fig. 5C). Conversely, unlike PUL-1, *M. tuberculosis* FadE13 demonstrated no E3 ligase activity
272 (Fig. 5D). Located at the putative acyl-CoA-binding site, a PUL-1 E361A mutant had no effect
273 on either the lack of dehydrogenase activity or the apparent E3 ligase activity (Fig. 5C-D).

274

275 As PUL-1 represents an unprecedented E3 ligase fold, we turned toward interpreting the
276 AlphaFold2 model in this perspective. Biochemical evidence suggested a Cys-based ligase
277 mechanism (Fig. 4B-D). Analysis of the relative surface accessible surface areas (SASA) for all
278 PUL-1 Cys residues highlighted Cys4 as the only one at the protein surface that could serve as an
279 active site (Fig. 5E-F). Located near the N-terminus, Cys4 directly precedes the first α -helix of
280 the PUL-1 fold (Fig. 5G). Mutation of Cys4 to alanine ablated PUL-1 ligase activity, whereas an

281 analogous mutation at Cys357 had no effect (**Fig. 5H**). Consistent with trapping the PUL-1~Ub
282 intermediate as a more stable oxyester linkage, mutation of Cys4 to serine resulted in a lower
283 molecular weight auto-ubiquitination product and no formation of unanchored diUb (**Fig. 5H**).
284 To confirm this prediction, we returned to assay conditions that allow observation of the early
285 PUL-1~Ub intermediate. While the wild-type PUL-1~Ub thioester intermediate was susceptible
286 to reduction with DTT, the intermediate formed with the C4S mutant was not, but instead could
287 be hydrolyzed by base treatment (**Fig. 5I**). Meanwhile, the PUL-1 C4A mutant showed no PUL-
288 1~Ub formation, confirming Cys4 as the active site. Lastly, the C4A mutation had no effect on
289 the lack of dehydrogenase activity demonstrated by PUL-1 (**Fig. 5C**). Among the tested *P.*
290 *aeruginosa* clinical isolates with secreted ligase activity (**Fig. 2F**), the PUL-1 sequence is highly
291 conserved and all examples carry the catalytic Cys4 residue (**Fig. S5C**). Interestingly, sequence
292 analysis outside of *P. aeruginosa* also identifies related acyl-CoA dehydrogenases with Cys or
293 Ser residues at this active site position, suggesting a wider adaptation of E3 ligase activity into
294 this common protein fold (**Fig. S5D**).

295

296 **PUL-1 ligase activity modulates *P. aeruginosa* virulence**

297 As *P. aeruginosa* PUL-1 could only function as an E3 ligase within the environment of a
298 eukaryotic host where the E1, E2, and Ub are present, we sought to assess its role as a virulence
299 factor. Consistent with this role, PUL-1 had no impact on the doubling time of *P. aeruginosa* in
300 culture (**Fig. 6A**). Furthermore, PUL-1 had no effect on *P. aeruginosa* motility, measured either
301 through swimming or swarming (**Fig. S6A-D**). Overall, the mechanisms of *P. aeruginosa*
302 pathogenesis are broadly conserved across mammalian, plant, and metazoan hosts. To determine
303 the role of PUL-1 in virulence, we used an established *C. elegans* model system⁵⁴. *P. aeruginosa*
304 infects and kills *C. elegans* through a process that mirrors infection in other hosts and correlates
305 with bacterial accumulation in the intestine.

306

307 To visualize the extent of intestinal infection, *P. aeruginosa* strains expressing DsRed
308 fluorescent protein were used to infect worms prior to visualization by fluorescence microscopy.
309 While the wild-type *P. aeruginosa* infection remained localized near the worm pharynx under
310 these conditions, in stark contrast the *pul-1*^{Tn} strain occupied the entire length of the intestine

311 (Fig. 6B). Accordingly, quantification of the bacterial burden by colony-forming units (CFU)
312 revealed a several log-fold increase following infection with the *pul-I^{Tn}* strain, compared to
313 wild-type (Fig. 6C). This effect on bacterial burden could be complemented with a wild-type
314 *pul-I* transgene expressed on a plasmid under its native promoter region (Fig. 6C). To test
315 whether this impact on virulence was linked to PUL-1 ligase activity, the *pul-I^{Tn}* mutant strain
316 was instead complemented with the structure-guided PUL-1 mutants. Complementation with the
317 C4A mutation, which ablated PUL-1 ligase activity (Fig. 5H), mimicked the *pul-I^{Tn}* mutant
318 strain and exhibited a higher bacterial burden (Fig. 6C). Interestingly, the C4S mutant, which
319 only restricted PUL-1 ligase activity (Fig. 5H), displayed an intermediate phenotype, whereas
320 the E361A mutant at the putative acyl-CoA-binding site behaved like wild-type (Fig. 6C).

321

322 Consistent with a higher bacterial burden, nematodes infected with the *pul-I^{Tn}* strain exhibited a
323 dramatic intestinal bloating phenotype compared to those fed with wild-type *P. aeruginosa* (Fig.
324 6D). This bloating phenotype was observed at both the head and the tail of the worms, and could
325 be restored to wild-type levels following complementation of the *pul-I^{Tn}* mutant strain with a
326 *pul-I* transgene (Fig. 6E-F, S6E). Complementation with the C4A and C4S mutations in the
327 PUL-1 ligase active site resulted in significant intestinal bloating similar to the *pul-I^{Tn}* strain
328 (Fig. 6E-F, S6E). Meanwhile, complementation with the E361A mutation at the putative acyl-
329 CoA-binding site restored bloating to levels observed with wild-type *P. aeruginosa* (Fig. 6E-F,
330 S6E).

331

332 The elevated burden and bloating phenotypes were associated with a significant decrease in the
333 lifespan of worms infected with the *pul-I^{Tn}* strain, compared to wild-type (Fig. 6G). Once again,
334 this effect was dependent upon the ligase activity of PUL-1, as infection with the C4A-
335 complemented mutant strain caused a similar reduction in lifespan to the *pul-I^{Tn}* strain (Fig. 6G).
336 Surprisingly, infection with the C4S-complemented mutant strain resulted in a lifespan similar to
337 the wild-type *P. aeruginosa* infection, suggesting that the restricted ligase activity of the serine
338 substitution retains some level of biologically relevant function. Infection with the E361A-
339 complemented strain, meanwhile, did not decrease lifespan compared to the wild-type infection.

340 Altogether, the *C. elegans* infections demonstrate a ligase-dependent role of PUL-1 in regulating
341 the virulence of *P. aeruginosa*.

342

343 DISCUSSION

344 The discovery of PUL-1 as a cryptic E3 Ub ligase lends further weight to the evolutionary
345 advantage of regulating Ub signaling during bacterial infection. That PUL-1 exhibited more of
346 an antivirulence role under these infection conditions was surprising, but not without
347 precedent^{55,56}. Other infection models may reveal a more traditional role, or PUL-1 might
348 function to modulate the level of *P. aeruginosa* virulence. While many bacterial ligases direct
349 Ub-dependent degradation of their targets, others instigate nondegradative signaling¹⁰. The
350 identity and fate of PUL-1 substrates, and their ties to its role in modulating virulence, will be an
351 interesting area of future research. One potential clue is the observation that a PUL-1 C4S mutant
352 complemented many of the phenotypes observed during *C. elegans* infection with the *pul-1^{Tn}*
353 strain. Based on our knowledge of eukaryotic Cys-based ligases, a serine mutation in the active
354 site should stabilize the E3~Ub intermediate and reduce or eliminate subsequent transfer. This is
355 consistent with the restricted ligase activity of the PUL-1 C4S mutant observed *in vitro*. That the
356 C4S mutant functions similarly to wild-type PUL-1 *in vivo*, however, suggests that either transfer
357 from a serine active site is possible under these conditions, or that the role of PUL-1 is to
358 ubiquitinate itself. Interestingly, many PUL-1 orthologues in other bacteria encode a serine at
359 this catalytic position, suggesting that some form of Ub ligase activity may be retained more
360 broadly.

361

362 The finding that PUL-1 catalyzes Ub conjugation through an acyl-CoA dehydrogenase protein
363 fold illustrates the importance of an unbiased approach in studying bacterial Ub regulators. PUL-
364 1 is not alone in this regard either; the SidE ligase family from *L. pneumophila* combines mono-
365 ADP-ribosyltransferase and phosphodiesterase activities to catalyze noncanonical, ATP-
366 independent ubiquitination⁵⁷. While our work has identified the catalytic center for PUL-1 ligase
367 function, how it engages with eukaryotic E2s for Ub transfer remains a topic for future work.
368 Structurally, PUL-1's ligase activity is spatially distinct from its putative acyl-CoA
369 dehydrogenase function. Though we do not observe dehydrogenase activity *in vitro*, we cannot

370 exclude that PUL-1 retains moonlighting activities. Moonlighting functions are not uncommon
371 among viral and bacterial proteins, even in conjunction with Ub regulation. Bacterial DUBs from
372 the CE clan of cysteine proteases can exhibit mixed Ub/Ub-like protease as well as
373 acetyltransferase activities through the same catalytic center^{33,58}. In the case of PUL-1, however,
374 the spatially removed Cys4 active site allowed for targeted elimination of specifically its ligase
375 function, thereby revealing an important role of PUL-1 ligase activity *in vivo*.

376

377 The approach we have developed to identify natively secreted Ub regulators offers several key
378 advantages over previous methods. First, it eliminates several biases that hinder the identification
379 of convergent activities: a) it is agnostic toward any sequence or structural similarities to known
380 Ub regulators, b) it avoids any presumptions about the mechanisms of Ub regulation, such that
381 they would react with activity-based probes, and c) it allows for discovery of previously
382 uncharacterized virulence factors. Secondly, the approach is highly versatile, both in the input
383 sample of bacterial proteins as well as in the reaction components. Through pre-treatment of
384 secreted fractions, or through swapping out the E2 in ligase assays, we could learn a great deal
385 about the nature of Ub regulation, before even identifying the responsible enzyme. It would also
386 be straightforward to introduce E2 or Ub mutations into the assay, in order to test dependency on
387 common interaction surfaces. Furthermore, though we focused on Ub, one could test for
388 conjugating, deconjugating, or binding activities toward ubiquitin-like modifiers by simply
389 exchanging the enzymes and substrates. A third key advantage of this approach is its synergy
390 with other methods. After observing and studying the activity in the mixture of secreted proteins,
391 one can quickly select a suitable activity-based probe for capture, enrichment, and identification
392 of the responsible enzyme. Alternatively, one could further purify the activity through
393 biochemical properties and fractionation, or through noncovalent interaction with the reaction
394 components. Lastly, where available, transposon mutant libraries offer a streamlined approach to
395 testing candidate proteins. Highlighted by benchmark studies in three bacteria and the successful
396 identification of a cryptic *P. aeruginosa* E3 ligase, this approach offers a compelling opportunity
397 to identify Ub regulators that modulate host-pathogen interactions and disease.

398

399 Though our approach offers many benefits in terms of eliminating bias and incorporating
400 versatility, there are several limitations in its current form. One limitation is the method used to
401 generate and harvest secreted effectors. While the stimuli we selected are widely utilized, they
402 are most likely not perfect mimics of a host infection and therefore may not trigger secretion to
403 the same extent. An alternative, which we took advantage of in the case of *S. flexneri*, is to also
404 test a mutant strain that constitutively secretes even in the absence of stimulation. Another
405 limitation is the lack of a eukaryotic environment in our assays for Ub regulation. This could
406 mean that cofactors or substrates required for activity are missing. While some effectors require
407 eukaryotic cofactors for function^{21,55,59}, this has not been observed for Ub regulation, likely
408 because such an activity would not be toxic to the bacterium prior to secretion and thus there
409 would be no selective pressure to establish spatiotemporal control. Incorporating protein-
410 depleted eukaryotic lysates into the approach could also account for required cofactors.
411 Regarding substrates, the monoUb-based substrate we used for monitoring DUB activity is
412 broadly applicable, but to detect linkage-specific DUB activities, fluorescent polyUb substrates
413 could be used instead⁶⁰. As for ligase activities, most E3 ligases will auto-ubiquitinate or produce
414 unanchored polyUb chains, even in the absence of substrate. Our initial approach for detecting
415 ligase activity also accounted for E2 selectivity by incorporating highly promiscuous E2s, but
416 additional E2s could easily be tested in parallel. Thus, with minor modifications, our approach
417 can be broadly applicable to diverse bacteria and forms of Ub regulation.

418

419 **MATERIALS AND METHODS**

420 *Bacterial strains and growth conditions*

421 *S. Typhimurium* SL1344 and secretion mutant strains were a kind gift from Dr. Leigh Knodler
422 (U. Vermont). EPEC O127:H6 strain E2348/69 was a kind gift from Dr. Brett Finlay (UBC). *S.*
423 *flexneri* M90T and secretion mutant strains were a kind gift from Dr. John Rohde (Dalhousie U.).
424 *P. aeruginosa* PAO1 and PA14, along with associated transposon or deletion mutant strains,
425 were accessed from the Ausubel and Manoil strain libraries^{49,50}. *P. aeruginosa* isolate PAHP3
426 was used previously⁶¹, and isolates JJ692 and E2 are part of a 20-strain diversity panel used
427 previously⁶². Other *P. aeruginosa* clinical isolates are from a panel of multidrug-resistant strains
428 isolated from pediatric patients with cystic fibrosis, described previously⁶³. *S. flexneri* strains

429 were cultured in Trypsin Soy Broth (TSB). All other strains were cultured in Luria-Bertani broth
430 (LB) at 37 °C with the following antibiotics, as required: Gentamicin 15 µg/mL, Tetracycline 5
431 µg/mL, Carbenicillin 200 µg/mL, Streptomycin 50 µg/mL, and Kanamycin 50 µg/mL.

432

433 *Cloning and mutagenesis*

434 The *PA2552* gene of *P. aeruginosa* was PCR amplified from PAO1 genomic DNA using primers
435 PA2552F (5'- AAGTTCTGTTTCAGGGCCCCGatgattccctgcaagaagag-3') and PA2552R (5'-
436 ATGGTCTAGAAAGCTTTActacaggctgcgacg-3') or PA2552F_pUCP18 (5'-
437 tcagatGGATCCcaacgtccacggcg-3') and PA2552R_pUCP18 (5'- tgagatAAGCTTctacaggctgcgcg-
438 3'). The amplified PA2552F/R DNA fragment was combined 1:3 vector:insert with linearized
439 pOPIN-B and transformed without ligation into TOP10 *E. coli* utilizing a rec-independent
440 process. The amplified PA2552F/R_pUCP18 DNA fragment was digested with BamHI and
441 HindIII before ligation into pUCP18 and propagation in TOP10 *E. coli*. PA2552 point mutations
442 C4A, C357A, and E361A of were performed using Quikchange PCR with PA2552_pUCP18 or
443 PA2552_pOPINB as template and primers PA2552C4AF (5'-
444 TCCCgcgGAAGAAGAGATCCAGATCCGT-3') and PA2552C4AR (5'-
445 CTTCcgcGGGAATCATCGCGGGT-3'), or PA2552C4AF (5'-
446 TCCCtcaGAAGAAGAGATCCAGATCCGT-3') and PA2552C4AR (5'-
447 CTTCtgaGGGAATCATCGCGGGT-3'), or PA2552E361AF (5'- CTACgcgGGCAccagegcagct-
448 3') and PA2552E361R (5'- TGCCcgcGTAGatctggcagacc-3') or PA2552C357F (5'-
449 GGTCgcgCAGATCTACGAGGG-3') and PA2552C357R (5'-TCTGcgcGACCCGCACGTCCC-
450 3'). Electrocompetent *P. aeruginosa* were prepared using the sucrose method according to Choi
451 et al⁶⁴. Transformants carrying the pUCP18 complementation plasmid were selected on LB agar
452 with Carbenicillin (200 µg/mL).

453

454 *Collection of secreted effectors*

455 Bacteria were plated onto agar containing selective antibiotics and grown overnight at 37 °C. All
456 effector preparations were generated from 25-50 mL of starting culture. For strains of *P.*
457 *aeruginosa*, single colonies were inoculated into sterile LB containing 5 mM EGTA and grown

458 at 37 °C with shaking at 215 rpm overnight. To harvest *S. Typhimurium* SPI-I effectors, strains
459 were first grown overnight in LB at 37 °C, then diluted from the overnight culture 1:300 in fresh
460 LB containing 300 mM NaCl and allowed to grow for 3 hours to mid-log phase at 37 °C with
461 shaking at 215 rpm. For isolation of *S. Typhimurium* SPI-II effectors, overnight cultures were
462 diluted 1:30 in MgM-MES media containing 170 mM 2-[N-morpholino]ethane-sulfonic acid
463 (MES), 5 mM KCl, 7.5 mM (NH₄)₂SO₄, 0.5 mM K₂SO₄, 1 mM KH₂PO₄, 8 μM MgCl₂, 38 mM
464 glycerol, and 0.1% casamino acids, set to a final pH of 5.0. The cultures were grown at 37 °C for
465 4 hours with shaking at 215 rpm, then the cells were pelleted and resuspended in 1 mL of 25 mM
466 sodium phosphate (pH 7.4), 150 mM NaCl and left standing at 37 °C for 1 hour. Red colonies of
467 *S. flexneri*, observed on TSB agar plates containing Congo red, were grown in liquid TSB
468 overnight at 37 °C with shaking at 215 rpm. Overnight cultures were then diluted 1:300 in TSB
469 and allowed to grow for 4 hours to mid-log phase at 37 °C with shaking at 215 rpm. Strains of
470 EPEC were grown overnight at 37 °C with shaking at 215 rpm in LB. Bacteria were then sub-
471 cultured 1:40 in pre-warmed Dulbecco's modified eagle medium (DMEM) and allowed to grow
472 standing at 37 °C with 5% CO₂ for 6 hours (until OD₆₀₀ reached 1).

473
474 Following stimulation of effector secretion, bacteria were pelleted by centrifugation at 2,400 xg
475 for 25 min. Pellets were freeze-thawed twice and treated with protease inhibitor cocktail
476 (MilliPore-Sigma) and 1 μg/mL lysozyme in 1 mL of 25 mM sodium phosphate (pH 7.4), 150
477 mM NaCl, 1 mM DTT for 30 min on ice. The lysate was clarified by centrifugation (29,000 xg,
478 10 min) and sterile filtering. Culture supernatants were sterile filtered and Tris buffer (pH 8.0)
479 was added to a final concentration of 25 mM before slowly adding ammonium sulfate powder to
480 a final percentage of 75% w/v. Ammonium sulfate was allowed to dissolve at 4 °C for 30 min
481 with light stirring. Precipitated proteins were collected by centrifugation at 35,000 xg for 30 min.
482 Pellets were resuspended in 0.5-1 mL of 25 mM sodium phosphate (pH 7.4), 150 mM NaCl, 0.5
483 mM DTT and dialyzed against the same buffer to remove excess ammonium sulfate. Samples
484 were subjected to Bradford assay to determine total protein concentration, normalized to 1-2
485 mg/mL, flash frozen in liquid nitrogen, and stored at -80 °C.

486

487 *SDS-PAGE analysis of secreted effector pools*

488 Samples of secreted and lysate fractions (5 ug) from each pathogen were diluted in reducing SDS
489 sample buffer and boiled for 5 mins at 98 °C. Proteins were resolved by 4-12% Tris-Glycine
490 SDS-PAGE (BioRad). Gels were fixed and silver stained according to the manufacturer's
491 protocol (BioRad).

492

493 *Recombinant protein production*

494 All recombinant proteins were produced in Rosetta *E. coli* (Millipore). Transformed cells were
495 cultured in LB at 37 °C until an OD₆₀₀ of 0.6-0.8, at which point protein expression was induced
496 with 0.2 mM IPTG and growth continued at 18 °C overnight. Cells were harvested by
497 centrifugation at 4,000 xg and resuspended in Buffer A: 25 mM Tris (pH 7.4), 200 mM NaCl, 2
498 mM 2-mercaptoethanol (with the exception of UBE1, which lacked reducing agent). Following a
499 freeze-thaw, cells were treated with protease inhibitor cocktail (Millipore-Sigma), 50 µg/mL
500 PMSF, 50 µg/mL DNase, and 200 µg/mL lysozyme for 30 min on ice. Samples were then lysed
501 by sonication and clarified by centrifugation at 35,000 xg for 30 min. UBE1 was purified by
502 activation onto GST-Ub-loaded glutathione resin, washed with 25 mM Tris (pH 7.4), 200 mM
503 NaCl, and eluted with the same buffer containing 10 mM DTT. The resulting elution was further
504 purified by size exclusion chromatography (Superdex75 pg, Cytiva). UBE2D3 and UBE2L3
505 were expressed without affinity tags and purified by cation exchange of clarified lysate in 30
506 mM MES pH 6.0, 1 mM EDTA, followed by size exclusion chromatography in 25 mM sodium
507 phosphate pH 7.4, 150 mM NaCl (Superdex75 pg, Cytiva).

508

509 His-tagged PUL-1 constructs were expressed as above and purified with cobalt resin using
510 standard procedures (ThermoFisher). Proteins were eluted with Buffer A containing 300 mM
511 imidazole and subjected to size exclusion chromatography in 50 mM HEPES (pH 8), 150 mM
512 NaCl, 0.5 mM DTT (Superdex75 pg, Cytiva). All proteins were concentrated using Amicon
513 centrifugal filters, quantified by absorbance, and flash frozen for storage at -80 °C.

514

515 *Fluorescence polarization assays*

516 FP DUB assays were adapted from Pruneda et al⁶⁵. A master solution with a final concentration
517 of 25 mM Tris (pH 7.4), 100 mM NaCl, 5 mM 2-mercaptoethanol, 0.1 mg/mL BSA, and 100 nM
518 Ub-KG(Tamra) was added to sample wells. FP measurements were made at room temperature
519 using a BMG LabTech ClarioStar with an excitation wavelength of 540 nm, an LP 566 nm
520 dichroic mirror, and an emission wavelength of 590 nm. FP was monitored for 10 cycles before
521 adding 10 µg of secreted or lysate fractions from *S. Typhimurium* and allowing the reaction to
522 continue for 2.5 hours. Each sample was prepared in triplicate, with the FP values averaged over
523 time points.

524

525 FP ligase assays were adapted from Franklin et al^{36,37}. A master solution with a final
526 concentration of 25 mM sodium phosphate (pH 7.4), 150 mM NaCl, 10 mM MgCl₂, 100 nM N-
527 terminally labeled Tamra-Ub, 125 nM UBE1, 2 µM E2 (UBE2D3 or UBE2L3) was added to
528 sample wells. To generate E2~T-Ub conjugate, 1 µl of 100 mM ATP was added to the
529 appropriate sample wells (5 mM final). FP measurements were made at room temperature using
530 a BMG LabTech ClarioStar with an excitation wavelength of 540 nm, an LP 566 nm dichroic
531 mirror, and an emission wavelength of 590 nm. FP was monitored for 10 cycles before adding 10
532 µg of secreted or lysate fractions from a given pathogen. Secreted fractions that were previously
533 boiled for 10 min at 98 °C, pre-treated with Proteinase K, or pre-treated with NEM, were used as
534 negative controls for ligase activity. FP was monitored for another 10 cycles to visualize early
535 Ub transfer events and/or noncovalent interactions between bacterial proteins and Tamra-Ub.
536 Subsequently, excess unlabeled Ub was introduced by adding 3 µl of 250 µM Ub, for a final
537 concentration of 37.5 µM. FP was then monitored for an additional 2 hours. Each sample was
538 prepared in triplicate, with the FP values averaged over time points.

539

540 *Gel-based ubiquitination assays*

541 10 µg of lysate/effector pool or 2 µM of purified PUL-1 were mixed with 125 nM E1, 2 µM E2,
542 37.5 µM Ub, 10 mM MgCl₂, and 5 mM ATP in 25 mM sodium phosphate (pH 7.4), 150 mM,
543 NaCl, 0.5 mM dithiothreitol (DTT). The reactions were incubated at 37 °C for 80 min and
544 terminated by the addition of reducing SDS sample buffer.

545

546 *Preparation of biotin-Ub-DHA*

547 Preparation of the Ub-DHA probe was adapted from Mulder et al⁴⁸. Ubiquitin with an N-
548 terminal AviTag and G76C mutation was incorporated into pOPIN-B. Protein expression and
549 cell lysis were performed as described above. The resulting clarified lysate was passed over pre-
550 equilibrated cobalt resin, allowing his-tagged Ub to bind (ThermoFisher). Resin was washed
551 with 1 L of Buffer A before eluting with Buffer A containing 300 mM imidazole. Eluted protein
552 was then concentrated with Amicon centrifugal filters and subjected to a biotinylation reaction
553 consisting of 100 μ M Avi-tagged protein, 5 μ l of 1M MgCl₂, 20 μ l of 100 mM ATP, 20 μ l of 50
554 μ M GST-BirA, and 3 μ l of 50 mM D-Biotin in 1 mL of 25 mM sodium phosphate (pH 7.4), 150
555 mM NaCl. The biotinylation reaction proceeded for 1 hr at 30 °C with light shaking. Following
556 size exclusion chromatography into of 25 mM sodium phosphate (pH 7.4), 150 mM NaCl
557 (Superdex75 pg, Cytiva), the resulting biotin-Ub-Cys product was treated with 5 mM DTT to
558 reduce the C-terminal cysteine, desalted into 50 mM sodium phosphate (pH 8.0), and
559 immediately reacted with 500-fold excess dibromohexandiamide (prepared at 300 mM in
560 DMSO). The reaction was incubated at room temperature for 3 hours, and excess
561 dibromohexandiamide was removed by desalting.

562

563 *Mass spectrometry sample preparation, in-gel digestion, and LC-MS*

564 To facilitate visualization and excision of Ub-DHA-reactive bands within the *P. aeruginosa*
565 effector pool, a fluorescent Cy5-labeled Ub-DHA probe was generated by total synthesis⁴⁸. 30 μ g
566 of Cy5-Ub-DHA was incubated with 0.5 mg of *P. aeruginosa* effector pool, 0.5 μ M E1, and 5
567 μ M UBE2D3 along with 10 mM MgCl₂ and 10 mM ATP for 2 hours at 37 °C. Reactions were
568 run into 4-12% SDS-PAGE gels, scanned at 658 nm for Cy5, and Coomassie stained. Gel bands
569 corresponding to 30, 40, and 50 kDa were excised from Ub-DHA-reacted and control samples,
570 sliced into small pieces, and incubated in 500 μ l acetonitrile at room temperature for 10 minutes.
571 Acetonitrile was removed, and disulfide bonds were reduced by adding 50 μ l of 10 mM DTT in
572 100 mM ammonium bicarbonate and incubation at 56 °C in a thermomixer with shaking at 400
573 rpm for 30 minutes. Samples were cooled to room temperature and washed once with 500 μ l
574 acetonitrile. After removing acetonitrile, gel slices were destained by addition of 100 μ l of 100

575 mM ammonium bicarbonate/acetonitrile (1:1 v/v) and incubation at room temperature for 30 min
576 in a thermomixer with shaking at 400 rpm. Destaining solution was discarded, and gel slices
577 were incubated in 500 μ l acetonitrile for 20 minutes at RT followed by decanting of acetonitrile
578 wash. Proteins were digested by submerging gel slices in 50 μ l of freshly prepared sequencing
579 grade trypsin (#22720, Affymetrix, Santa Clara, CA) at 13 ng/ μ l in 10 mM ammonium
580 bicarbonate containing 10% acetonitrile (v/v). Digestion was performed overnight in a
581 thermomixer at 37 °C with heated lid and shaking at 400 rpm. Peptides were extracted by
582 addition of extraction buffer (1:2 (v/v) 5% formic acid/acetonitrile) at a 2:1 extraction
583 buffer/sample (v/v) ratio, and incubation for 15 min at 37 °C. Peptides were concentrated to
584 dryness in a vacuum centrifuge, resuspended in 10 μ l of 5% acetonitrile, and transferred to a new
585 vial. Residual peptides were collected by washing the original tryptic peptide tube with 10 μ l
586 water and added to the new vial.

587
588 Approximately 500 ng of peptides were injected onto a primary trap column (4 cm x 150 μ m i.d.
589 packed with 5 μ m Jupiter C18 particles (Phenomenex, Torrance, CA)) and separated in a
590 capillary column (70 cm x 75 μ m i.d. packed with 3 μ m Jupiter C18 particles). Peptides were
591 separated with 0.1% formic acid in acetonitrile (mobile phase B) and 0.1% formic acid in water
592 (mobile phase A) at a 300 nl/min flow rate. The elution gradient consisted of 20 minutes at 12%
593 B, 75 min at 30% B, and 97 min at 45% B. Eluting peptides were analyzed by an inline
594 quadrupole orbitrap mass spectrometer (Q-Exactive HF, Thermo Fisher Scientific, San Jose,
595 CA). Spectra were collected in the 300-1,800 m/z range at 70,000-mass resolution. Data
596 dependent acquisition of tandem MS/MS spectra were obtained for the 12 most intense ions
597 using high-energy collision dissociation with 17,500-mass resolution and a dynamic exclusion of
598 30 seconds. Raw MS data were analyzed by Maxquant (v.1.6.14.0) using default parameters and
599 a *P. aeruginosa* protein sequence collected from Uniprot (accessed August 2020). A 1% false
600 discovery rate was used at both peptide and protein levels. For quantification, intensity-based
601 absolute quantification (iBAQ) was used, and all subsequent analysis was performed using
602 Perseus (v1.6.5.0). Proteins were filtered to remove potential contaminants, followed by log₂
603 transformation and imputation of missing values with intensity of zero.

604

605 Analysis of Ub linkage sites was performed following an *in vitro* ubiquitination reaction
606 composed of 2 μ M PUL-1, 125 nM E1, 2 μ M E2, 37.5 μ M Ub, 10 mM $MgCl_2$, and 5 mM ATP
607 in 25 mM sodium phosphate (pH 7.4), 150 mM, NaCl, 0.5 mM DTT. The reaction was incubated
608 at 37 °C for 120 min and terminated by the addition of reducing SDS sample buffer. The samples
609 were run into 4-12% SDS-PAGE gels and Coomassie stained. Gel bands corresponding to
610 PUL1-Ub and diUb were excised and processed as above for mass spectrometry analysis.

611

612 *Immunoblotting*

613 Protein samples were resolved by 4-12% Tris-Glycine SDS-PAGE (BioRad) and transferred
614 onto 0.22 μ m nitrocellulose membranes. Membranes were blocked with Tris-buffered saline
615 containing 0.1% (w/v) Tween-20 (TBS-T) with 5% (w/v) non-fat dried skimmed milk powder at
616 room temperature for 1 hr. Membranes were subsequently probed with indicated antibodies in
617 TBS-T containing 3% (w/v) bovine serum albumin overnight at 4 °C. Horseradish peroxidase
618 (HRP)-conjugated secondary antibodies in TBS-T were then blotted for 1 hr at room
619 temperature, prior to visualization with ECL. Ubiquitin was probed with 1:1000 anti-ubiquitin
620 primary antibody (clone Ubi-1, Millipore MAB1510). Biotin was probed with 1:1000 anti-biotin
621 primary antibody (Bethyl Laboratories, A150-109A).

622

623 *Ub-DHA profiling of PUL-1*

624 3 μ M recombinant PUL-1 was mixed with 500 nM E1, 5 μ M E2, 50 μ M Biotin-Ub-DHA, 10
625 mM $MgCl_2$, and 5 mM ATP in 50 mM HEPES (pH 8.0), 150 mM NaCl, 1 mM DTT. The
626 reactions were incubated at 37 °C for 80 min and supplemented with 1 mM ATP every 20 min.
627 To remove isopeptide- and thioester-linked Ub-DHA complexes, USP21 (0.5 μ M) was added to
628 the resulting sample along with 5 mM DTT and incubated for an additional 30 min at 37 °C.
629 Reactions were then terminated by the addition of reducing SDS sample buffer.

630

631 *Acyl-CoA dehydrogenase activity assay*

632 Acyl-CoA dehydrogenase assays were carried out using the DCPIP method, which measures the
633 reduction of DCPIP as an electron acceptor downstream of PMS as an intermediate electron

634 carrier. Assays were carried out under the following conditions: 50 mM HEPES-KOH buffer (pH
635 8.0), 50 μ M FAD, 100 μ g/mL DCPIP, 100 μ g/mL PMS, 50 μ M octanoyl-CoA lithium salt, and 1
636 μ M enzyme. Reactions were performed at room temperature in technical triplicate and initiated
637 by the addition of octanoyl-CoA lithium salt. DCPIP reduction was measured by the decrease in
638 absorbance at 600 nm in clear, flat-bottom, 96-well plates.

639

640 *PUL-1 thioester trapping assay*

641 A master mix containing 125 nM E1, 2 μ M UBE2L3, 37.5 μ M Ub, 2 μ M PUL-1, and 10 mM
642 MgCl₂ was prepared in 25 mM sodium phosphate (pH 7.0), 150 mM NaCl. The reaction was
643 then initiated by the addition of 5 mM ATP and incubated for 7 min (WT) or 20 min (C4S and
644 C4A) at 37 °C. The reactions were terminated by the addition of nonreducing SDS sample
645 buffer. Resulting samples were either left untreated, reduced with 10 mM DTT, or treated with
646 0.010 N NaOH.

647

648 *Bioinformatic analysis*

649 PUL-1 orthologues were identified by PSI-BLAST and Phyre2 searches^{66,67}. The sequences were
650 aligned using Jalview Software and TCOffee^{68,69}. Protein structural models were obtained from
651 the AlphaFold Protein Structure Database⁵¹, analyzed for homology with DALI⁵², and visualized
652 with PyMol (www.pymol.org).

653

654 *C. elegans growth conditions*

655 *C. elegans* hermaphrodites were maintained on *E. coli* OP50 at 20 °C unless otherwise indicated.
656 Bristol N2 was used as the wild-type control obtained from the *Caenorhabditis* Genetics Center
657 (University of Minnesota, Minneapolis, MN). The bacterial strain *E. coli* OP50 was grown in LB
658 broth at 37 °C.

659

660 *Quantification of intestinal bacterial loads*

661 Animals were synchronized by placing gravid adults on modified nematode growth media
662 (NGM) agar plates (0.35% instead of 0.25% peptone) containing *E. coli* OP50 for 2 hours at 20
663 °C. The gravid adults were removed, leaving the eggs to hatch and develop at 20 °C. For
664 quantification of colony forming units (CFU), bacterial lawns were prepared by spreading 50 µL
665 of overnight culture on the complete surface of 6 cm-diameter modified NGM agar plates. The
666 plates were incubated at 37 °C for 12-16 hours and then cooled to room temperature for at least 1
667 hour before seeding with young gravid adult hermaphroditic animals. Animals were exposed to
668 the *P. aeruginosa* lawns for 24 hours at 25 °C, after which the animals were transferred to the
669 center of fresh *E. coli* plates for 30 min to eliminate bacteria stuck to their body. Animals were
670 then transferred to the center of a new *E. coli* plate for 30 min to further eliminate external
671 bacteria. Animals were finally transferred to fresh *E. coli* plates a third time for 10 min.
672 Afterward, ten animals/condition were transferred into 50 µL of PBS plus 0.01% Triton X-100
673 and ground. Ten-fold serial dilutions of the lysates were seeded onto LB plates containing 5
674 µg/mL doxycycline with or without 200 µg/mL of carbenicillin to select for *P. aeruginosa* and
675 grown overnight at 37 °C. Single colonies were counted the next day and used to calculate CFU
676 per animal. Three independent experiments were performed for each condition.

677

678 *Quantification of intestinal lumen bloating*

679 Synchronized young adult *C. elegans* hermaphrodites were transferred to modified NGM plates
680 containing *P. aeruginosa* lawns and incubated at 25 °C for 24 hours. After the indicated
681 treatment, the animals were anesthetized using an M9 salt solution containing 50 mM sodium
682 azide and mounted onto 2% agar pads. The animals were then visualized using a Leica M165 FC
683 fluorescence stereomicroscope. The diameter of the intestinal lumen was measured using Image
684 J software. At least 10 animals were used for each condition.

685

686 *C. elegans killing assays*

687 Bacterial lawns were prepared on modified NGM plates as indicated above. Synchronized young
688 adult *C. elegans* hermaphrodites were transferred *P. aeruginosa* lawns and incubated at 25 °C.
689 Animals were scored at the indicated times for survival and transferred to fresh pathogen lawns

690 each day until no progeny was produced. Animals were considered dead when they failed to
691 respond to touch and no pharyngeal pumping was observed. Each experiment was performed in
692 triplicate (n = 90 animals).

693

694 *Quantification and statistical analysis*

695 Statistical analysis was performed with Prism 7 (Graph Pad). The Kaplan Meier method was
696 used to calculate the survival fractions, and statistical significance between survival curves was
697 determined using the log-rank test.

698

699 **ACKNOWLEDGEMENTS**

700 We thank David Komander (WEHI) and Rachel Klevit (UW) for sharing expression plasmids,
701 and Leigh Knodler (U. Vermont), Brett Finlay (UBC), and John Rohde (Dalhousie U.) for
702 sharing bacterial strains. We thank members of our laboratories and the Seattle Ub Research
703 Group for helpful discussions. This work was facilitated, in part, by the PMedIC joint research
704 collaboration between OHSU and the Pacific Northwest National Laboratory (PNNL), which is a
705 multi-program national laboratory operated by Battelle for the DOE under Contract DE-AC05-
706 76RL01830. This work was supported by the Laboratory Directed Research and Development
707 Program at PNNL (ESN), the IARPA FunGCAT program (the funders had no role in the design
708 or interpretation of the experiments) (JNA), Oregon Health & Science University (JNP), the
709 Medical Research Foundation of Oregon (JNP), the NIH National Institute of Allergy and
710 Infectious Diseases (R01AI156900 to AA and R21AI176089 to NK), and the NIH National
711 Institute of General Medical Sciences (R37GM070977 to AA and R35GM142486 to JNP).

712

713 **AUTHOR CONTRIBUTIONS**

714 Conceptualization, JNP; Investigation, CGR, SK, AJO, MED, GDW, and JNP; Resources, AK,
715 NVK, PPG, MPCM, JEM, JNA, and AA; Writing – original draft, CGR and JNP; Writing –
716 review & editing, all authors; Supervision, JNP; Funding acquisition, ESN, JNA, NK, AA, and
717 JNP.

718

719 **COMPETING INTEREST STATEMENT**

720 The authors declare no competing interests.

721

722 **REFERENCES**

- 723 1. Komander, D., and Rape, M. (2012). The ubiquitin code. *Annu Rev Biochem* *81*, 203-
724 229. [10.1146/annurev-biochem-060310-170328](https://doi.org/10.1146/annurev-biochem-060310-170328).
- 725 2. Swatek, K.N., and Komander, D. (2016). Ubiquitin modifications. *Cell Res* *26*, 399-422.
726 [10.1038/cr.2016.39](https://doi.org/10.1038/cr.2016.39).
- 727 3. Pao, K.C., Wood, N.T., Knebel, A., Rafie, K., Stanley, M., Mabbitt, P.D.,
728 Sundaramoorthy, R., Hofmann, K., van Aalten, D.M.F., and Virdee, S. (2018). Activity-
729 based E3 ligase profiling uncovers an E3 ligase with esterification activity. *Nature* *556*,
730 381-385. [10.1038/s41586-018-0026-1](https://doi.org/10.1038/s41586-018-0026-1).
- 731 4. Otten, E.G., Werner, E., Crespillo-Casado, A., Boyle, K.B., Dharamdasani, V., Pathe, C.,
732 Santhanam, B., and Randow, F. (2021). Ubiquitylation of lipopolysaccharide by RNF213
733 during bacterial infection. *Nature* *594*, 111-116. [10.1038/s41586-021-03566-4](https://doi.org/10.1038/s41586-021-03566-4).
- 734 5. Metzger, M.B., Pruneda, J.N., Klevit, R.E., and Weissman, A.M. (2014). RING-type E3
735 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination.
736 *Biochim Biophys Acta* *1843*, 47-60. [10.1016/j.bbamcr.2013.05.026](https://doi.org/10.1016/j.bbamcr.2013.05.026).
- 737 6. Lorenz, S. (2018). Structural mechanisms of HECT-type ubiquitin ligases. *Biol Chem*
738 *399*, 127-145. [10.1515/hsz-2017-0184](https://doi.org/10.1515/hsz-2017-0184).
- 739 7. Cotton, T.R., and Lechtenberg, B.C. (2020). Chain reactions: molecular mechanisms of
740 RBR ubiquitin ligases. *Biochem Soc Trans* *48*, 1737-1750. [10.1042/BST20200237](https://doi.org/10.1042/BST20200237).
- 741 8. Roberts, C.G., Franklin, T.G., and Pruneda, J.N. (2023). Ubiquitin-targeted bacterial
742 effectors: rule breakers of the ubiquitin system. *EMBO J* *42*, e114318.
743 [10.15252/embj.2023114318](https://doi.org/10.15252/embj.2023114318).
- 744 9. Mukherjee, R., and Dikic, I. (2022). Regulation of Host-Pathogen Interactions via the
745 Ubiquitin System. *Annu Rev Microbiol* *76*, 211-233. [10.1146/annurev-micro-041020-025803](https://doi.org/10.1146/annurev-micro-041020-025803).
- 747 10. Franklin, T.G., and Pruneda, J.N. (2021). Bacteria make surgical strikes on host ubiquitin
748 signaling. *PLoS Pathog* *17*, e1009341. [10.1371/journal.ppat.1009341](https://doi.org/10.1371/journal.ppat.1009341).
- 749 11. Lin, Y.H., Lucas, M., Evans, T.R., Abascal-Palacios, G., Doms, A.G., Beauchene, N.A.,
750 Rojas, A.L., Hierro, A., and Machner, M.P. (2018). RavN is a member of a previously
751 unrecognized group of *Legionella pneumophila* E3 ubiquitin ligases. *PLoS Pathog* *14*,
752 e1006897. [10.1371/journal.ppat.1006897](https://doi.org/10.1371/journal.ppat.1006897).
- 753 12. Abramovitch, R.B., Janjusevic, R., Stebbins, C.E., and Martin, G.B. (2006). Type III
754 effector AvrPtoB requires intrinsic E3 ubiquitin ligase activity to suppress plant cell
755 death and immunity. *Proc Natl Acad Sci U S A* *103*, 2851-2856.
756 [10.1073/pnas.0507892103](https://doi.org/10.1073/pnas.0507892103).
- 757 13. Schubert, A.F., Nguyen, J.V., Franklin, T.G., Geurink, P.P., Roberts, C.G., Sanderson,
758 D.J., Miller, L.N., Ovaa, H., Hofmann, K., Pruneda, J.N., and Komander, D. (2020).


- 759 Identification and characterization of diverse OTU deubiquitinases in bacteria. *EMBO J*
760 *39*, e105127. 10.15252/embj.2020105127.
- 761 14. Misaghi, S., Balsara, Z.R., Catic, A., Spooner, E., Ploegh, H.L., and Starnbach, M.N.
762 (2006). Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells
763 during infection. *Mol Microbiol* *61*, 142-150. 10.1111/j.1365-2958.2006.05199.x.
- 764 15. McDermott, J.E., Cort, J.R., Nakayasu, E.S., Pruneda, J.N., Overall, C., and Adkins, J.N.
765 (2019). Prediction of bacterial E3 ubiquitin ligase effectors using reduced amino acid
766 peptide fingerprinting. *PeerJ* *7*, e7055. 10.7717/peerj.7055.
- 767 16. Wan, M., Wang, X., Huang, C., Xu, D., Wang, Z., Zhou, Y., and Zhu, Y. (2019). A
768 bacterial effector deubiquitinase specifically hydrolyses linear ubiquitin chains to inhibit
769 host inflammatory signalling. *Nat Microbiol* *4*, 1282-1293. 10.1038/s41564-019-0454-1.
- 770 17. Tanner, K., Brzovic, P., and Rohde, J.R. (2015). The bacterial pathogen-ubiquitin
771 interface: lessons learned from Shigella. *Cell Microbiol* *17*, 35-44. 10.1111/cmi.12390.
- 772 18. Antimicrobial Resistance, C. (2022). Global burden of bacterial antimicrobial resistance
773 in 2019: a systematic analysis. *Lancet* *399*, 629-655. 10.1016/S0140-6736(21)02724-0.
- 774 19. Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., and Wu, M.
775 (2022). Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance,
776 interaction with host, technology advances and emerging therapeutics. *Signal Transduct*
777 *Target Ther* *7*, 199. 10.1038/s41392-022-01056-1.
- 778 20. Balachandran, P., Dragone, L., Garrity-Ryan, L., Lemus, A., Weiss, A., and Engel, J.
779 (2007). The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated
780 virulence. *J Clin Invest* *117*, 419-427. 10.1172/JCI28792.
- 781 21. Anderson, D.M., Schmalzer, K.M., Sato, H., Casey, M., Terhune, S.S., Haas, A.L., Feix,
782 J.B., and Frank, D.W. (2011). Ubiquitin and ubiquitin-modified proteins activate the
783 Pseudomonas aeruginosa T3SS cytotoxin, ExoU. *Mol Microbiol* *82*, 1454-1467.
784 10.1111/j.1365-2958.2011.07904.x.
- 785 22. Rytkonen, A., Poh, J., Garmendia, J., Boyle, C., Thompson, A., Liu, M., Freemont, P.,
786 Hinton, J.C., and Holden, D.W. (2007). SseL, a Salmonella deubiquitinase required for
787 macrophage killing and virulence. *Proc Natl Acad Sci U S A* *104*, 3502-3507.
788 10.1073/pnas.0610095104.
- 789 23. Zhang, Y., Higashide, W.M., McCormick, B.A., Chen, J., and Zhou, D. (2006). The
790 inflammation-associated Salmonella SopA is a HECT-like E3 ubiquitin ligase. *Mol*
791 *Microbiol* *62*, 786-793. 10.1111/j.1365-2958.2006.05407.x.
- 792 24. Valleau, D., Little, D.J., Borek, D., Skarina, T., Quaile, A.T., Di Leo, R., Houlston, S.,
793 Lemak, A., Arrowsmith, C.H., Coombes, B.K., and Savchenko, A. (2018). Functional
794 diversification of the NleG effector family in enterohemorrhagic Escherichia coli. *Proc*
795 *Natl Acad Sci U S A* *115*, 10004-10009. 10.1073/pnas.1718350115.
- 796 25. Rohde, J.R., Breitkreutz, A., Chenal, A., Sansonetti, P.J., and Parsot, C. (2007). Type III
797 secretion effectors of the IpaH family are E3 ubiquitin ligases. *Cell Host Microbe* *1*, 77-
798 83. 10.1016/j.chom.2007.02.002.
- 799 26. Yu, X.J., McGourty, K., Liu, M., Unsworth, K.E., and Holden, D.W. (2010). pH sensing
800 by intracellular Salmonella induces effector translocation. *Science* *328*, 1040-1043.
801 10.1126/science.1189000.
- 802 27. Bahrani, F.K., Sansonetti, P.J., and Parsot, C. (1997). Secretion of Ipa proteins by
803 Shigella flexneri: inducer molecules and kinetics of activation. *Infect Immun* *65*, 4005-
804 4010. 10.1128/iai.65.10.4005-4010.1997.

- 805 28. Menard, R., Sansonetti, P.J., and Parsot, C. (1993). Nonpolar mutagenesis of the ipa
806 genes defines IpaB, IpaC, and IpaD as effectors of *Shigella flexneri* entry into epithelial
807 cells. *J Bacteriol* 175, 5899-5906. 10.1128/jb.175.18.5899-5906.1993.
- 808 29. Kenny, B., Abe, A., Stein, M., and Finlay, B.B. (1997). Enteropathogenic *Escherichia*
809 *coli* protein secretion is induced in response to conditions similar to those in the
810 gastrointestinal tract. *Infect Immun* 65, 2606-2612. 10.1128/iai.65.7.2606-2612.1997.
- 811 30. Galan, J.E., and Curtiss, R., 3rd (1990). Expression of *Salmonella typhimurium* genes
812 required for invasion is regulated by changes in DNA supercoiling. *Infect Immun* 58,
813 1879-1885. 10.1128/iai.58.6.1879-1885.1990.
- 814 31. Bajaj, V., Lucas, R.L., Hwang, C., and Lee, C.A. (1996). Co-ordinate regulation of
815 *Salmonella typhimurium* invasion genes by environmental and regulatory factors is
816 mediated by control of hilA expression. *Mol Microbiol* 22, 703-714. 10.1046/j.1365-
817 2958.1996.d01-1718.x.
- 818 32. Geurink, P.P., El Oualid, F., Jonker, A., Hameed, D.S., and Ovaa, H. (2012). A general
819 chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay
820 reagents. *Chembiochem* 13, 293-297. 10.1002/cbic.201100706.
- 821 33. Pruneda, J.N., Durkin, C.H., Geurink, P.P., Ovaa, H., Santhanam, B., Holden, D.W., and
822 Komander, D. (2016). The Molecular Basis for Ubiquitin and Ubiquitin-like Specificities
823 in Bacterial Effector Proteases. *Mol Cell* 63, 261-276. 10.1016/j.molcel.2016.06.015.
- 824 34. Pfeifer, C.G., Marcus, S.L., Steele-Mortimer, O., Knodler, L.A., and Finlay, B.B. (1999).
825 *Salmonella typhimurium* virulence genes are induced upon bacterial invasion into
826 phagocytic and nonphagocytic cells. *Infect Immun* 67, 5690-5698.
827 10.1128/IAI.67.11.5690-5698.1999.
- 828 35. Brumell, J.H., Rosenberger, C.M., Gotto, G.T., Marcus, S.L., and Finlay, B.B. (2001).
829 SifA permits survival and replication of *Salmonella typhimurium* in murine
830 macrophages. *Cell Microbiol* 3, 75-84. 10.1046/j.1462-5822.2001.00087.x.
- 831 36. Franklin, T.G., and Pruneda, J.N. (2019). A High-Throughput Assay for Monitoring
832 Ubiquitination in Real Time. *Front Chem* 7, 816. 10.3389/fchem.2019.00816.
- 833 37. Franklin, T.G., and Pruneda, J.N. (2023). Observing Real-Time Ubiquitination in High
834 Throughput with Fluorescence Polarization. *Methods Mol Biol* 2581, 3-12. 10.1007/978-
835 1-0716-2784-6_1.
- 836 38. Franklin, T.G., Brzovic, P.S., and Pruneda, J.N. (2023). Bacterial ligases reveal
837 fundamental principles of polyubiquitin specificity. *Mol Cell* 83, 4538-4554 e4534.
838 10.1016/j.molcel.2023.11.017.
- 839 39. Quezada, C.M., Hicks, S.W., Galan, J.E., and Stebbins, C.E. (2009). A family of
840 *Salmonella* virulence factors functions as a distinct class of autoregulated E3 ubiquitin
841 ligases. *Proc Natl Acad Sci U S A* 106, 4864-4869. 10.1073/pnas.0811058106.
- 842 40. Bernal-Bayard, J., and Ramos-Morales, F. (2009). *Salmonella* type III secretion effector
843 SlrP is an E3 ubiquitin ligase for mammalian thioredoxin. *J Biol Chem* 284, 27587-
844 27595. 10.1074/jbc.M109.010363.
- 845 41. Stewart, M.D., Ritterhoff, T., Klevit, R.E., and Brzovic, P.S. (2016). E2 enzymes: more
846 than just middle men. *Cell Res* 26, 423-440. 10.1038/cr.2016.35.
- 847 42. Chou, Y.C., Keszei, A.F.A., Rohde, J.R., Tyers, M., and Sicheri, F. (2012). Conserved
848 structural mechanisms for autoinhibition in IpaH ubiquitin ligases. *J Biol Chem* 287, 268-
849 275. 10.1074/jbc.M111.316265.

- 850 43. Hospenthal, M.K., Mevissen, T.E.T., and Komander, D. (2015). Deubiquitinase-based
851 analysis of ubiquitin chain architecture using Ubiquitin Chain Restriction (UbiCRest).
852 *Nat Protoc* 10, 349-361. 10.1038/nprot.2015.018.
- 853 44. Kimbrough, T.G., and Miller, S.I. (2000). Contribution of *Salmonella typhimurium* type
854 III secretion components to needle complex formation. *Proc Natl Acad Sci U S A* 97,
855 11008-11013. 10.1073/pnas.200209497.
- 856 45. Klein, J.A., Grenz, J.R., Slauch, J.M., and Knodler, L.A. (2017). Controlled Activity of
857 the *Salmonella* Invasion-Associated Injectisome Reveals Its Intracellular Role in the
858 Cytosolic Population. *MBio* 8. 10.1128/mBio.01931-17.
- 859 46. McCaw, M.L., Lykken, G.L., Singh, P.K., and Yahr, T.L. (2002). ExsD is a negative
860 regulator of the *Pseudomonas aeruginosa* type III secretion regulon. *Mol Microbiol* 46,
861 1123-1133. 10.1046/j.1365-2958.2002.03228.x.
- 862 47. Frank, D.W. (1997). The exoenzyme S regulon of *Pseudomonas aeruginosa*. *Mol*
863 *Microbiol* 26, 621-629. 10.1046/j.1365-2958.1997.6251991.x.
- 864 48. Mulder, M.P., Witting, K., Berlin, I., Pruneda, J.N., Wu, K.P., Chang, J.G., Merckx, R.,
865 Bialas, J., Groettrup, M., Vertegaal, A.C., et al. (2016). A cascading activity-based probe
866 sequentially targets E1-E2-E3 ubiquitin enzymes. *Nat Chem Biol* 12, 523-530.
867 10.1038/nchembio.2084.
- 868 49. Liberati, N.T., Urbach, J.M., Miyata, S., Lee, D.G., Drenkard, E., Wu, G., Villanueva, J.,
869 Wei, T., and Ausubel, F.M. (2006). An ordered, nonredundant library of *Pseudomonas*
870 *aeruginosa* strain PA14 transposon insertion mutants. *Proc Natl Acad Sci U S A* 103,
871 2833-2838. 10.1073/pnas.0511100103.
- 872 50. Jacobs, M.A., Alwood, A., Thaipisuttikul, I., Spencer, D., Haugen, E., Ernst, S., Will, O.,
873 Kaul, R., Raymond, C., Levy, R., et al. (2003). Comprehensive transposon mutant library
874 of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 100, 14339-14344.
875 10.1073/pnas.2036282100.
- 876 51. Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan,
877 D., Stroe, O., Wood, G., Laydon, A., et al. (2022). AlphaFold Protein Structure Database:
878 massively expanding the structural coverage of protein-sequence space with high-
879 accuracy models. *Nucleic Acids Res* 50, D439-D444. 10.1093/nar/gkab1061.
- 880 52. Holm, L. (2020). Using Dali for Protein Structure Comparison. *Methods Mol Biol* 2112,
881 29-42. 10.1007/978-1-0716-0270-6_3.
- 882 53. Battaile, K.P., Molin-Case, J., Paschke, R., Wang, M., Bennett, D., Vockley, J., and Kim,
883 J.J. (2002). Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with
884 acetoacetyl-CoA: comparison with other acyl-CoA dehydrogenases. *J Biol Chem* 277,
885 12200-12207. 10.1074/jbc.M111296200.
- 886 54. Tan, M.W., Mahajan-Miklos, S., and Ausubel, F.M. (1999). Killing of *Caenorhabditis*
887 *elegans* by *Pseudomonas aeruginosa* used to model mammalian bacterial pathogenesis.
888 *Proc Natl Acad Sci U S A* 96, 715-720. 10.1073/pnas.96.2.715.
- 889 55. Pruneda, J.N., Smith, F.D., Daurie, A., Swaney, D.L., Villen, J., Scott, J.D., Stadnyk,
890 A.W., Le Trong, I., Stenkamp, R.E., Klevit, R.E., et al. (2014). E2~Ub conjugates
891 regulate the kinase activity of *Shigella* effector OspG during pathogenesis. *EMBO J* 33,
892 437-449. 10.1002/embj.201386386.
- 893 56. Kubori, T., Hyakutake, A., and Nagai, H. (2008). *Legionella* translocates an E3 ubiquitin
894 ligase that has multiple U-boxes with distinct functions. *Mol Microbiol* 67, 1307-1319.
895 10.1111/j.1365-2958.2008.06124.x.

- 896 57. Qiu, J., Sheedlo, M.J., Yu, K., Tan, Y., Nakayasu, E.S., Das, C., Liu, X., and Luo, Z.Q.
897 (2016). Ubiquitination independent of E1 and E2 enzymes by bacterial effectors. *Nature*
898 533, 120-124. 10.1038/nature17657.
- 899 58. Pruneda, J.N., Bastidas, R.J., Bertsoulaki, E., Swatek, K.N., Santhanam, B., Clague, M.J.,
900 Valdivia, R.H., Urbe, S., and Komander, D. (2018). A Chlamydia effector combining
901 deubiquitination and acetylation activities induces Golgi fragmentation. *Nat Microbiol* 3,
902 1377-1384. 10.1038/s41564-018-0271-y.
- 903 59. Mittal, R., Peak-Chew, S.Y., Sade, R.S., Vallis, Y., and McMahon, H.T. (2010). The
904 acetyltransferase activity of the bacterial toxin YopJ of *Yersinia* is activated by
905 eukaryotic host cell inositol hexakisphosphate. *J Biol Chem* 285, 19927-19934.
906 10.1074/jbc.M110.126581.
- 907 60. Geurink, P.P., van Tol, B.D., van Dalen, D., Brundel, P.J., Mevissen, T.E., Pruneda, J.N.,
908 Elliott, P.R., van Tilburg, G.B., Komander, D., and Ovaa, H. (2016). Development of
909 Diubiquitin-Based FRET Probes To Quantify Ubiquitin Linkage Specificity of
910 Deubiquitinating Enzymes. *ChemBiochem* 17, 816-820. 10.1002/cbic.201600017.
- 911 61. Shah, K.N., Shah, P.N., Mullen, A.R., Chen, Q., Southerland, M.R., Chirra, B.,
912 DeBerardinis, R.J., and Cannon, C.L. (2020). N-Acetyl cysteine abrogates silver-induced
913 reactive oxygen species in human cells without altering silver-based antimicrobial
914 activity. *Toxicol Lett* 332, 118-129. 10.1016/j.toxlet.2020.07.014.
- 915 62. Lee, D.G., Urbach, J.M., Wu, G., Liberati, N.T., Feinbaum, R.L., Miyata, S., Diggins,
916 L.T., He, J., Saucier, M., Deziel, E., et al. (2006). Genomic analysis reveals that
917 *Pseudomonas aeruginosa* virulence is combinatorial. *Genome Biol* 7, R90. 10.1186/gb-
918 2006-7-10-r90.
- 919 63. Kang, D., Revtovich, A.V., Chen, Q., Shah, K.N., Cannon, C.L., and Kirienko, N.V.
920 (2019). Pyoverdine-Dependent Virulence of *Pseudomonas aeruginosa* Isolates From
921 Cystic Fibrosis Patients. *Front Microbiol* 10, 2048. 10.3389/fmicb.2019.02048.
- 922 64. Choi, K.H., and Schweizer, H.P. (2006). mini-Tn7 insertion in bacteria with single attTn7
923 sites: example *Pseudomonas aeruginosa*. *Nat Protoc* 1, 153-161. 10.1038/nprot.2006.24.
- 924 65. Pruneda, J.N., and Komander, D. (2019). Evaluating enzyme activities and structures of
925 DUBs. *Methods Enzymol* 618, 321-341. 10.1016/bs.mie.2019.01.001.
- 926 66. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and
927 Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein
928 database search programs. *Nucleic Acids Res* 25, 3389-3402. 10.1093/nar/25.17.3389.
- 929 67. Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J. (2015). The
930 Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc* 10, 845-858.
931 10.1038/nprot.2015.053.
- 932 68. Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009).
933 Jalview Version 2--a multiple sequence alignment editor and analysis workbench.
934 *Bioinformatics* 25, 1189-1191. 10.1093/bioinformatics/btp033.
- 935 69. Notredame, C., Higgins, D.G., and Heringa, J. (2000). T-Coffee: A novel method for fast
936 and accurate multiple sequence alignment. *J Mol Biol* 302, 205-217.
937 10.1006/jmbi.2000.4042.


Fig 1. A functional screen for ubiquitin regulation



940 **Figure 1: A functional screen for ubiquitin regulation**

- 941 A. Schematic for the strategy used to stimulate effector secretion in bacterial culture
942 prior to harvesting the secreted and lysate fractions.
- 943 B. Silver-stained SDS-PAGE analysis of secreted (**S**) and lysate (**L**) fractions prepared
944 following stimulation as indicated.
- 945 C. Schematic for the FP-based assay for detection of DUB activity.
- 946 D. Representative FP traces monitoring the Ub-KG(Tamra) DUB substrate following
947 addition of the indicated pools of *S. Typhimurium* protein.
- 948 E. Schematic for the FP-based assay for detection of E3 ligase activity.
- 949 F. Representative FP traces monitoring the Tamra-Ub ligase substrate following
950 addition of the indicated pools of *S. Typhimurium* protein. At the indicated
951 timepoints, additional unlabeled Ub or the DUB vOTU were added to stimulate
952 product extension or deconjugation, respectively.
- 953 G. Representative FP traces monitoring the Tamra-Ub ligase substrate following
954 addition of the indicated bacterial secreted fractions to reactions containing the
955 promiscuous E2 enzyme, UBE2D3.
- 956 H. As in **G**), for reactions containing the Cys-specific E2 enzyme, UBE2L3.
957


Fig 2. Detection of E3 ligase activity secreted by *P. aeruginosa*



958 **Figure 2: Detection of E3 ligase activity secreted by *P. aeruginosa***

- 959 A. Silver-stained SDS-PAGE analysis of secreted (**S**) and lysate (**L**) fractions prepared
960 following EGTA stimulation of *P. aeruginosa* PAO1 and PA14 strains.
- 961 B. Representative FP traces monitoring the Tamra-Ub ligase substrate following
962 addition of the PA14 secreted fraction. At the indicated timepoints, additional
963 unlabeled Ub or the DUB vOTU were added to stimulate product extension or
964 deconjugation, respectively.
- 965 C. Representative FP traces monitoring the Tamra-Ub ligase substrate following
966 addition of either the PA14 or PAO1 secreted fractions to reactions containing either
967 the promiscuous E2 UBE2D3 or the Cys-specific E2 UBE2L3.
- 968 D. Representative FP traces monitoring the Tamra-Ub ligase substrate following
969 addition of the PA14 secreted fraction that was untreated, pre-treated with NEM or
970 Proteinase K (ProtK), or generated without stimulation with EGTA.
- 971 E. Representative FP traces monitoring the Tamra-Ub ligase substrate following
972 addition of secreted fractions generated from the indicated PA14 mutant strains.
- 973 F. Final FP values of the Tamra-Ub ligase substrate following addition of secreted
974 fractions from the indicated *P. aeruginosa* clinical isolates.
975

Fig 3. Identification of a *P. aeruginosa* E3 ligase




976 **Figure 3: Identification of a *P. aeruginosa* E3 ligase**

- 977 A. Silver-stained SDS-PAGE analysis of the PA14 secreted fraction following stepwise
978 ammonium sulfate fractionation.
- 979 B. Final FP values of the Tamra-Ub ligase substrate following addition of the indicated
980 ammonium sulfate fractions of PA14 secreted protein.
- 981 C. Reactivity of the cascading Ub-DHA activity-based probe with the indicated
982 ammonium sulfate fractions of PA14 secreted protein. Reactions were resolved by
983 SDS-PAGE and visualized by western blot for the biotinylated Ub-DHA probe.
984 Reacted proteins, including putative probe-reactive PA14 effectors, are labeled with
985 an asterisk.
- 986 D. Final FP values of the Tamra-Ub ligase substrate following addition of secreted
987 fractions generated from the indicated *P. aeruginosa* mutant strains, which test ligase
988 candidates from bioinformatic prediction, ABP-MS analysis, or known effectors.
- 989 E. Representative FP traces monitoring the Tamra-Ub ligase substrate following
990 addition of secreted fractions generated from PAO1 wild-type, the *pul-I*^{Tn} mutant
991 strain, or a *pul-I*^{Tn} mutant strain complemented with *pul-1*.
992

993 **Figure 4: Characterization of PUL-1 E3 ligase activity**

- 994 A. Coomassie-stained SDS-PAGE analysis of recombinantly purified PUL-1.
- 995 B. E3 ligase assays for recombinant PUL-1, including conditions with pre-treatment of
996 NEM or post-treatment of the DUB USP21. Reactions were resolved by SDS-PAGE
997 and visualized by Ponceau stain and anti-Ub western blot.
- 998 C. Time course monitoring reactivity of the cascading Ub-DHA activity-based probe
999 with recombinant PUL-1. Reactions were resolved by SDS-PAGE and visualized by
1000 Coomassie stain or anti-Ub western blot. Reacted proteins are labeled with an
1001 asterisk.
- 1002 D. E3 ligase assays for recombinant PUL-1 and the indicated panel of E2 enzymes.
1003 Reactions were resolved by SDS-PAGE and visualized by anti-Ub western blot.
- 1004 E. UbiCRest assay of PUL-1 ligase products. A PUL-1 ligase reaction was treated with
1005 the indicated panel of linkage-specific DUBs, a combination of all linkage-specific
1006 DUBs, or the indicated nonspecific DUBs. Reactions were resolved by SDS-PAGE
1007 and visualized by anti-Ub western blot.
- 1008 F. Amino acid reactivity analysis of the activated PUL-1~Ub thioester intermediate.
1009 PUL-1 was loaded with Ub, and discharge was monitored following addition of DTT
1010 or the indicated amino acids. Reactions were resolved by SDS-PAGE and visualized
1011 by Coomassie stain.
1012


Fig 5. Structural analysis of the PUL-1 ligase fold



1013 **Figure 5: Structural analysis of the PUL-1 ligase fold**

- 1014 A. AlphaFold2 model of PUL-1, colored by pLDDT confidence scores, with N- and C-
1015 termini labeled.
- 1016 B. Structural overlay of the AlphaFold2 models of PUL-1, putative acyl-CoA
1017 dehydrogenases from *M. tuberculosis* (Mtb) and *B. thailandensis* (Bt, PDB: 4M9A),
1018 and the mitochondrial short-chain specific acyl-CoA dehydrogenase (SCAD, PDB:
1019 1JQI) from rat. C-alpha root mean square deviation (RMSD) values are listed.
- 1020 C. Octanoyl-CoA dehydrogenase activity assay monitoring reduction of DCPIP at 600
1021 nm wavelength.
- 1022 D. E3 ligase assays for recombinant PUL-1 and FadE13. Reactions were resolved by
1023 SDS-PAGE and visualized by Ponceau stain and anti-Ub western blot.
- 1024 E. AlphaFold2 model of PUL-1 (green), with surface representation (grey) and all Cys
1025 residues highlighted (red).
- 1026 F. Relative solvent-accessible surface area (SASA) of each Cys residue within the PUL-
1027 1 AlphaFold2 model.
- 1028 G. Detailed view of Cys4 within the PUL-1 AlphaFold2 model, with Cys4 (red) and
1029 neighboring residues shown as ball-and-stick.
- 1030 H. E3 ligase assays for wild-type or the indicated PUL-1 mutants. Reactions were
1031 resolved by SDS-PAGE and visualized by Ponceau stain and anti-Ub western blot.
- 1032 I. Chemical stability toward reducing agent (DTT) or basic pH (NaOH) of the activated
1033 UBE2L3~Ub and PUL-1~Ub intermediates. Enzymes were loaded with Ub, and
1034 discharge was monitored following the indicated chemical treatments. Reactions were
1035 resolved by SDS-PAGE and visualized by Ponceau stain.
- 1036


Fig 6. PUL-1 ligase activity modulates *P. aeruginosa* virulence



1037 **Figure 6: PUL-1 ligase activity modulates *P. aeruginosa* virulence**

- 1038 A. Growth curves for wild-type (WT) and the PAO1 *pul-I^{Tn}* mutant strain in LB, with
1039 doubling times (T_d) indicated.
- 1040 B. Representative fluorescent images of *C. elegans* infected with WT and the PAO1 *pul-*
1041 *I^{Tn}* mutant strain expressing DsRed.
- 1042 C. Bacterial burden measured as colony-forming units (CFU) per worm, following
1043 infection with the indicated PAO1 strains. Mean values and standard deviation are
1044 indicated in red. Significance was determined by one-way ANOVA with Dunnett's
1045 multiple comparisons test.
- 1046 D. Representative images of *C. elegans* intestinal bloating near the head, following
1047 infection with WT or the PAO1 *pul-I^{Tn}* mutant strain. The intestinal lumen diameter
1048 is indicated by red arrows.
- 1049 E. Quantification of *C. elegans* intestinal lumen diameter near the head following
1050 infection with the indicated PAO1 strains. Median values are shown in red.
1051 Significance was determined by one-way ANOVA with Dunnett's multiple
1052 comparisons test.
- 1053 F. As in E), for intestinal lumen diameters near the tail.
- 1054 G. Survival curves for *C. elegans* infected with the indicated PAO1 strains. Significance
1055 was determined by the Log-rank (Mantel-Cox) test.
1056

Fig S1. A functional screen for ubiquitin regulation



1057 **Supplementary Figure 1: A functional screen for ubiquitin regulation**

1058 A. E3 ligase assays combining the indicated reaction components with the SPI-I secreted
1059 fraction from *S. Typhimurium*, with and without prior treatment with NEM.

1060 Reactions were resolved by SDS-PAGE and visualized by anti-Ub western blot.

1061 B. As in **A**), for the secreted fraction from EPEC.


1062 C. As in **A**), for the secreted fraction from *S. flexneri*.

1063

1064 **Supplementary Figure 2: Detection of E3 ligase activity secreted by *P. aeruginosa***

- 1065 A. Silver-stained SDS-PAGE analysis of secreted fractions generated from the indicated
1066 PA14 mutant strains, or in the absence of EGTA stimulation.
- 1067 B. Silver-stained SDS-PAGE analysis of secreted fractions generated from the indicated
1068 *P. aeruginosa* clinical isolates.
- 1069 C. Representative FP traces monitoring the Tamra-Ub ligase substrate following
1070 addition of secreted fractions from the indicated *P. aeruginosa* clinical isolates.
1071


Fig S3. Identification of a *P. aeruginosa* E3 ligase



1072 **Supplementary Figure 3: Identification of a *P. aeruginosa* E3 ligase**

- 1073 A. Representative FP traces monitoring the Tamra-Ub ligase substrate following
1074 addition of the indicated ammonium sulfate fractions of PA14 secreted protein.
- 1075 B. E3 ligase assays for secreted fractions generated from PAO1 wild-type or the
1076 *PA2552^{Tn}* mutant strain. Reactions were resolved by SDS-PAGE and visualized by
1077 anti-Ub western blot.
1078

Fig S4. Characterization of PUL-1 E3 ligase activity




1079 **Supplementary Figure 4: Characterization of PUL-1 E3 ligase activity**


- 1080 A. E3 ligase assays for recombinant PUL-1 and the indicated panel of E2 enzymes.
1081 Ponceau-stained visualization of **Figure 4D**.
- 1082 B. E3 ligase assays for recombinant PUL-1 and Lys-less (K0), methylated, or the
1083 indicated panel of K-only Ub mutants. Reactions were resolved by SDS-PAGE and
1084 visualized by anti-Ub western blot.
- 1085 C. E3 ligase assays for recombinant PUL-1 and Lys-less (K0), methylated, or the
1086 indicated panel of K-to-R Ub mutants. Reactions were resolved by SDS-PAGE and
1087 visualized by anti-Ub western blot.
- 1088 D. Ubiquitination sites identified by mass spectrometry following an *in vitro* PUL-1
1089 ligase reaction.
1090

Fig S5. Structural analysis of the PUL-1 ligase fold

A



B



C

Strain	PUL-1 sequence substitutions (relative to PAO1)
PAO1	-
PA14	A372V
PA2-45	None
PA2-59	None
PA2-61	E7D, T220A
PA2-72	None
PA2-88	None
PA2-89	None
PA2-94	None
PA3-17	None
PA3-22	None
PA3-25	None
PA5-40	None
PAHP3	None
E2	R260C
JJ692	None


D

	Active site
<i>Pseudomonas aeruginosa</i> PAO1 NP_251242.1	MIP---C E E E I Q I
<i>Pseudomonas aeruginosa</i> UCBPP-PA14 ABJ11732.1	MIP---C E E E I Q I
<i>Acinetobacter baumannii</i> SST13011.1	MIP---C E E E I Q I
<i>Pseudomonas otitidis</i> WP_165675478.1	MIP---S E D D I Q I
<i>Pseudomonas alcaligenes</i> WP_203792207.1	MLP---S E Q D L L I
<i>Pseudomonas syringae</i> WP_004418511.1	M H D L E L S E E Q V M I
<i>Pseudomonas nitritireducens</i> WP_184593261.1	MIP---S E E D I Q I
<i>Pseudomonas fluorescens</i> WP_039768646.1	MIP---N D D Q Q Q I
<i>Pseudomonas putida</i> WP_019437599.1	MLV---N D E Q Q Q I

1091 **Supplementary Figure 5: Structural analysis of the PUL-1 ligase fold**

- 1092 A. Structural overlay of the mitochondrial short-chain specific acyl-CoA dehydrogenase
1093 (SCAD) from rat (yellow, PDB: 1JQI), with acetoacetyl-CoA bound (grey sticks),
1094 and the PUL-1 AlphaFold2 model (green). Residues within the acyl-CoA-binding
1095 pocket are shown in ball-and-stick for both enzymes.
- 1096 B. Structural overlay of the mitochondrial short-chain specific acyl-CoA dehydrogenase
1097 (SCAD) from rat (yellow, PDB: 1JQI), with FAD bound (grey sticks), and the PUL-1
1098 AlphaFold2 model (green). Residues within the FAD-binding pocket are shown in
1099 ball-and-stick for both enzymes.
- 1100 C. Conservation of PUL-1 orthologues among all *P. aeruginosa* clinical isolates
1101 presented in **Figure 2F**. Amino acid substitutions relative to PAO1 are listed.
- 1102 D. Sequence alignment of PUL-1 orthologues, focused on the region surrounding Cys4
1103 of PAO1.
1104

Fig S6. PUL-1 ligase activity modulates *P. aeruginosa* virulence



1105 **Supplementary Figure 6: PUL-1 ligase activity modulates *P. aeruginosa* virulence**

1106 A. Representative images of *P. aeruginosa* swimming for WT PAO1 and the indicated
1107 *pul-I*^{Tn} mutant strains.

1108 B. Quantification of **A**), under conditions with and without EGTA. Mean values and
1109 standard deviation are indicated in red.

1110 C. Representative images of *P. aeruginosa* swarming for WT PAO1 and the indicated
1111 *pul-I*^{Tn} mutant strains.

1112 D. Quantification of **C**). Mean values and standard deviation are indicated in red.

1113 E. Representative images of *C. elegans* intestinal bloating near the head and tail,
1114 following infection with WT PAO1 or the indicated *pul-I*^{Tn} mutant strains. The
1115 intestinal lumen diameter is indicated by black arrows.

1116